TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Regist...(allow foradjustment of baseline differen...),Health

In the pooled ARRIVE 1 and 2 registry analysis, the TAXUS Stent maintained comparable re-intervention rates in the diabetic and non-diabetic patient populations. Cumulative two-year TLR rates, whether adjusted (7.1% vs. 6.8%, p=0.41) or unadjusted (8.2% vs. 7.7%, p=0.59), were similar between diabetic and non-diabetic patients, respectively. Diabetic patients in the higher-risk subgroup actually had lower adjusted TLR rates than non-diabetic patients (7.2% vs. 8.6%, p=0.03). Analysis of multivariate predictors showed that diabetes is not a significant predictor of TLR at two years in patients treated with the TAXUS Stent.

Safety outcomes at two years showed that diabetic patients treated with the TAXUS Stent in the ARRIVE registry had similar rates of MI (3.1% vs. 2.5%, p=0.35, adjusted) and ARC definite/probable stent thrombosis (2.3% vs. 1.9%, p=0.34, adjusted) compared to non-diabetic patients, whether or not multivariate adjustment was used. The results also showed that diabetic patients had the expected increase in two-year mortality compared to patients without diabetes (7.0% vs. 3.9%, p<0.001, adjusted), as well as increased cardiac death (4.3% vs. 2.1%, p<0.001), reflecting the more advanced cardiac disease and increased comorbid risk factors associated with diabetes. While diabetes was shown to be an independent predictor of mortality at two years in the overall study sample, the strongest predictors of two-year mortality in both the overall sample and in diabetic patients were renal disease, treated left main disease and congestive heart failure.

"Our extensive ARRIVE registries provide valuable insights into the benefits of the TAXUS Stent in treating diabetic patients who are often at higher risk for adverse event
'/>"/>